This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Hydroxysteroid 17- β dehydrogenase 1 (HSD17B1)	<p>Studies in cell cultures suggest that thienopyrimidinone inhibitors of HSD17B1 could help treat hormone-dependent breast cancer. Inhibiting HSD17B1 is known to decrease hormone-dependent breast tumor growth in animals. <i>In vitro</i>, a screen of 19 thienopyrimidinone analogs identified a lead compound that inhibited HSD17B1 at low micromolar levels in a human breast cancer cell line. Next steps could include testing the lead compound in animal models of breast cancer.</p> <p>SciBX 2(41); doi:10.1038/scibx.2009.1528 Published online Oct. 22, 2009</p>	Patent and licensing status unavailable	<p>Lilienkampf, A. <i>et al. J. Med. Chem.</i>; published online Oct. 13, 2009; doi:10.1021/jm900928k</p> <p>Contact: Kristiina Wähälä, University of Helsinki, Helsinki, Finland e-mail: kristiina.wahala@helsinki.fi</p>